U.S. FDA Approves an Additional Indication for CAPVAXIVE® in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each With WELIREG® , for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma
Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
FDA Grants Breakthrough Therapy Designation for Calderasib , an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoints of Overall Survival and Progression-Free Survival in Certain Patients With Advanced or Recurrent Endometrial Cancer
